Readies R & D facilities for Ap3ana, CTI's 'personalized medicine' venture
SEATTLE, Oct. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) announced today that Christina A. Waters, Ph.D., M.B.A., most recently President and COO of a Tyr Pharma and formerly Director of Scientific Development at Genomics Institute of the Novartis Research Foundation, has been named President of CTI Europe. Based in Bresso, Italy, CTI Europe currently conducts the research and development of CTI's cancer drug pipeline.
"With her specialized background in genomics, hands on experience in integrating research and development operations, and proven strategic portfolio development capabilities, Dr. Waters, a Howard Hughes Fellow, is an excellent choice to lead the Bresso unit," said James A. Bianco, M.D., CEO of CTI. "She will bring the necessary knowledge and experience in oncology to direct Bresso's world-class scientists and bridge R&D with Translational Medicine," Bianco added.
"Leading the Bresso operation is a great opportunity as it will be a key part of the foundation on which we build Ap(3)ana. This is truly the time when we will see major advancements made in health care and we intend to be at the heart of it," Dr. Waters said.
In her new role as President of CTI Europe, Dr. Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies in the areas of informatics, genetics, preclinical and clinical development to advance medical treatment and predictive medicine.
Ap(3)ana is expected to combine Bresso's R & D capabilities with the
advanced genomic screening of CTI's Systems Medicine subsidiary, and novel
computational technologies of The Translational
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved